UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling

PloS one, 2014-09, Vol.9 (9), p.e107142

2014

Volltextzugriff (PDF)

Epigenetic basis of cancer health disparities: Looking beyond genetic differences

Biochimica et biophysica acta. Reviews on cancer, 2017-08, Vol.1868 (1), p.16-28

2017

Volltextzugriff (PDF)

MicroRNAs in Gynecological Cancers: Small molecules with big implications

Cancer letters, 2017-10, Vol.407, p.123-138

2017

Volltextzugriff (PDF)

Impact of Travel Time on Health Care Costs and Resource Use by Phase of Care for Older Patients With Cancer

Journal of clinical oncology, 2019-08, Vol.37 (22), p.1935-1945

2019

Volltextzugriff (PDF)

Corrigendum to “Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.” [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015]

Neoplasia (New York, N.Y.), 2024-04, Vol.50, p.100978-100978, Article 100978

2024

Volltextzugriff (PDF)

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer

Gynecologic oncology, 2020-02, Vol.156 (2), p.393-399

2020

Volltextzugriff (PDF)

CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival

Clinical & experimental metastasis, 2012-12, Vol.29 (8), p.939-948

2012

Volltextzugriff (PDF)

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

The lancet oncology, 2020-12, Vol.21 (12), p.1661-1672

2020

Volltextzugriff (PDF)

Validation of a venous thromboembolism risk assessment model in gynecologic oncology

Gynecologic oncology, 2014-07, Vol.134 (1), p.160-163

2014

Volltextzugriff (PDF)

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

The lancet oncology, 2015-06, Vol.16 (6), p.686-694

2015

Volltextzugriff (PDF)

Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells

International journal of oncology, 2011-10, Vol.39 (4), p.797-804

2011

Volltextzugriff (PDF)

Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition

Neoplasia (New York, N.Y.), 2021-09, Vol.23 (9), p.1002-1015

2021

Volltextzugriff (PDF)

Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a “second look”

Gynecologic oncology, 2019-08, Vol.154 (2), p.290-293

2019

Volltextzugriff (PDF)

The trend towards minimally invasive surgery (MIS) for endometrial cancer: An ACS–NSQIP evaluation of surgical outcomes

Gynecologic oncology, 2015-03, Vol.136 (3), p.512-515

2015

Volltextzugriff (PDF)

A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen

Gynecologic oncology, 2022-01, Vol.164 (1), p.181-186

2022

Volltextzugriff (PDF)

Minority participation in Gynecologic Oncology Group (GOG) Studies

Gynecologic oncology, 2015-08, Vol.138 (2), p.441-444

2015

Volltextzugriff (PDF)

Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity

Gynecologic oncology, 2020-06, Vol.157 (3), p.729-732

2020

Volltextzugriff (PDF)

Molecular profiles of endometrial cancer tumors among Black patients

Gynecologic oncology, 2022-07, Vol.166 (1), p.108-116

2022

Volltextzugriff (PDF)

Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers

International journal of gynecological cancer, 2021-11, Vol.31 (11), p.1403-1407

2021

Volltextzugriff (PDF)

Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement

The lancet oncology, 2023-10, Vol.24 (10), p.e415-e423

2023

Volltextzugriff (PDF)

The limited utility of currently available venous thromboembolism risk assessment tools in gynecologic oncology patients

American journal of obstetrics and gynecology, 2016-11, Vol.215 (5), p.673-674

2016

Volltextzugriff (PDF)

Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response

Cancers, 2023-11, Vol.15 (23), p.5616

2023

Volltextzugriff (PDF)

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer

Gynecologic oncology, 2021-12, Vol.163 (3), p.459-464

2021

Volltextzugriff (PDF)

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy

Future oncology (London, England), 2024-08, p.1-16

2024

Volltextzugriff (PDF)

Gli1 Protein Regulates the S-phase Checkpoint in Tumor Cells via Bid Protein, and Its Inhibition Sensitizes to DNA Topoisomerase 1 Inhibitors

The Journal of biological chemistry, 2014-11, Vol.289 (45), p.31513-31525

2014

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(145)

Publikationsform

Artikel
(169)
Buchkapitel
(1)

Sprache

Englisch
(170)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(98)
Humans
(76)
Oncology
(76)
Female
(73)
Obstetrics & Gynecology
(54)
Ovarian Cancer
(41)
Middle Aged
(38)
Adult
(23)
Aged
(23)
Hematology, Oncology And Palliative Medicine
(18)
Neoplasm Staging
(18)
Obstetrics And Gynecology
(18)
Ovarian Neoplasms - Drug Therapy
(18)
Tumors
(18)
Ovarian Neoplasms - Pathology
(17)
Retrospective Studies
(16)
Biological And Medical Sciences
(15)
Chemotherapy
(15)
Medical Sciences
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling

Epigenetic basis of cancer health disparities: Looking beyond genetic differences

MicroRNAs in Gynecological Cancers: Small molecules with big implications

Impact of Travel Time on Health Care Costs and Resource Use by Phase of Care for Older Patients With Cancer

Corrigendum to “Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.” [Neoplasia Volume 23, Issue 9, September 2021, Pages 1002-1015]

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer

CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Validation of a venous thromboembolism risk assessment model in gynecologic oncology

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells

Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition

Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a “second look”

The trend towards minimally invasive surgery (MIS) for endometrial cancer: An ACS–NSQIP evaluation of surgical outcomes

A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen

Minority participation in Gynecologic Oncology Group (GOG) Studies

Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity

Molecular profiles of endometrial cancer tumors among Black patients

Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers

Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement

The limited utility of currently available venous thromboembolism risk assessment tools in gynecologic oncology patients

Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy

Gli1 Protein Regulates the S-phase Checkpoint in Tumor Cells via Bid Protein, and Its Inhibition Sensitizes to DNA Topoisomerase 1 Inhibitors

Suchergebnisse filtern